Search

Displaying results 5641 - 5650 of 8974 in total
  1. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  2. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    Human ciliary neurotrophic factor, recombinant was investigated for macular telangiectasia in two clinical trials. … The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia

  3. Drug

    LY3884961

    go.drugbank.com/drugs/DB17070
    Investigational

    LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]

  4. Drug

    MBP-091

    go.drugbank.com/drugs/DB17741
    Experimental

    MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]

  5. Drug

    Salacetamide

    go.drugbank.com/drugs/DB20217
    Investigational

    Salacetamide is under investigation in clinical trial NCT00220285 (Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma).

  6. Drug

    Butylamine

    go.drugbank.com/drugs/DB03659
    Experimental

    It is one of the four isomeric amines of butane. It is known to have the fishy, ammonia-like odor common to amines.

  7. Drug

    Resorcinol monoacetate

    go.drugbank.com/drugs/DB15480
    ApprovedWithdrawn

    Mixtures: Thomas Formula No 28
  8. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  9. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes. … [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation

  10. Drug

    Chamaecyparis obtusa leaf

    go.drugbank.com/drugs/DB14686
    Investigational

    Mixtures: Rhodd Ato Repair Body So Ap